Journal Published Online: 01 April 1975
Volume 20, Issue 2

Fatal Anaphylaxis After Intravenous Iron Dextran

CODEN: JFSCAS

Abstract

Iron dextran (Imferon®) is a complex of ferric iron and dextran widely used for the treatment of iron deficiency anemia. It became commercially available in the United States in 1957. Since that time the intramuscular administration of iron dextran has been considered a relatively safe manner of administering iron to patients unable to tolerate oral iron therapy. However, untoward side effects have been reported. The most common of these are discomfort or staining of the skin at the injection site. The more disturbing reactions, however, appear to be allergic in nature and include lymphadenopathy, fever, urticaria, angioneurotic edema, arthralgias, and transient shocklike conditions [1–5]. Recently four cases of fatal anaphylaxis following intramuscular injection of iron dextran have been reported [6,7].

Author Information

Zipf, RE
Riverside Hospital Laboratories, Columbus, Ohio
Pages: 8
Price: $25.00
Related
Reprints and Permissions
Reprints and copyright permissions can be requested through the
Copyright Clearance Center
Details
Stock #: JFS10279J
ISSN: 0022-1198
DOI: 10.1520/JFS10279J